{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:42:33Z","timestamp":1776300153155,"version":"3.50.1"},"reference-count":54,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T00:00:00Z","timestamp":1597622400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP11544347"],"award-info":[{"award-number":["APP11544347"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns4:p>COVID-19 emerged in late 2019 and has rapidly spread through many countries globally. The causative SARS-CoV-2 virus was not known until recently, and there is little or no natural immunity in human populations. There is an urgent need for vaccines and drugs to combat this new pandemic. In just a few months, huge efforts and resources by government, academia, and industry have been thrown into the race to develop a vaccine. This brief review summarizes and discusses the array of technologies being applied to vaccine development, highlighting the strengths and weaknesses of the various approaches.<\/ns4:p>","DOI":"10.12688\/f1000research.25998.1","type":"journal-article","created":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T12:45:09Z","timestamp":1597668309000},"page":"991","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":45,"title":["Development of vaccines for SARS-CoV-2"],"prefix":"10.12688","volume":"9","author":[{"given":"Wern Hann","family":"Ng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3141-8410","authenticated-orcid":false,"given":"Suresh","family":"Mahalingam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2560","published-online":{"date-parts":[[2020,8,17]]},"reference":[{"key":"ref-1","doi-asserted-by":"publisher","first-page":"264-6","DOI":"10.1016\/j.ijid.2020.01.009","article-title":"The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China.","volume":"91","author":"D Hui","year":"2020","journal-title":"Int J Infect Dis."},{"key":"ref-2","article-title":"Coronavirus disease (COVID-2019) situation reports","year":"2020"},{"key":"ref-3","article-title":"WHO Director-General's opening remarks at the media briefing on COVID-19 - 13 March 2020","year":"2020"},{"key":"ref-4","article-title":"With record-setting speed, vaccinemakers take their first shots at the new coronavirus.","author":"J Cohen","year":"2020","journal-title":"Science."},{"key":"ref-5","article-title":"Draft landscape of Covid-19 candidate vaccines","year":"2020"},{"key":"ref-6","article-title":"Clinical Trials","year":"2020"},{"key":"ref-7","doi-asserted-by":"publisher","first-page":"305-6","DOI":"10.1038\/d41573-020-00073-5","article-title":"The COVID-19 vaccine development landscape.","volume":"19","author":"T Le","year":"2020","journal-title":"Nat Rev Drug Discov."},{"key":"ref-8","doi-asserted-by":"publisher","first-page":"225-49","DOI":"10.3390\/vaccines1030225","article-title":"Vector Design for Improved DNA Vaccine Efficacy, Safety and Production.","volume":"1","author":"J Williams","year":"2013","journal-title":"Vaccines (Basel)."},{"key":"ref-9","doi-asserted-by":"publisher","first-page":"1316-27","DOI":"10.1016\/j.ymthe.2017.03.035","article-title":"Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses.","volume":"25","author":"K Bahl","year":"2017","journal-title":"Mol Ther."},{"key":"ref-10","doi-asserted-by":"publisher","first-page":"14604-9","DOI":"10.1073\/pnas.1209367109","article-title":"Nonviral delivery of self-amplifying RNA vaccines.","volume":"109","author":"A Geall","year":"2012","journal-title":"Proc Natl Acad Sci U S A."},{"key":"ref-11","doi-asserted-by":"publisher","first-page":"248-51","DOI":"10.1038\/nature21428","article-title":"Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination.","volume":"543","author":"N Pardi","year":"2017","journal-title":"Nature."},{"key":"ref-12","doi-asserted-by":"publisher","first-page":"594","DOI":"10.3389\/fimmu.2019.00594","article-title":"Advances in mRNA Vaccines for Infectious Diseases.","volume":"10","author":"C Zhang","year":"2019","journal-title":"Front Immunol."},{"key":"ref-13","doi-asserted-by":"publisher","first-page":"3605","DOI":"10.3390\/ijms19113605","article-title":"DNA Vaccines-How Far From Clinical Use?","volume":"19","author":"D Hobernik","year":"2018","journal-title":"Int J Mol Sci."},{"key":"ref-14","article-title":"Inovio Inovio Initiates Phase 1 Clinical Trial Of Its COVID-19 Vaccine and Plans First Dose Today","year":"2020"},{"key":"ref-15","article-title":"Inovio IVI, INOVIO, and KNIH to Partner with CEPI in Phase 1\/2 Clinical Trial of INOVIO's COVID-19 DNA Vaccine in South Korea","year":"2020"},{"key":"ref-16","article-title":"Moderna Moderna Announces Award from U.S. Government Agency BARDA for up to $483 Million to Accelerate Development of mRNA Vaccine (mRNA-1273) Against Novel Coronavirus","year":"2020"},{"key":"ref-17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA Vaccine against SARS-CoV-2 \u2014 Preliminary Report.","author":"L Jackson","year":"2020","journal-title":"N Engl J Med."},{"key":"ref-18","article-title":"Moderna Moderna Advances Late-Stage Development of its Vaccine (mRNA-1273) Against COVID-19","year":"2020"},{"key":"ref-19","doi-asserted-by":"publisher","first-page":"2181-7","DOI":"10.1016\/S0140-6736(04)17590-9","article-title":"Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector.","volume":"364","author":"H Gaspar","year":"2004","journal-title":"Lancet."},{"key":"ref-20","doi-asserted-by":"publisher","first-page":"624-41","DOI":"10.3390\/vaccines2030624","article-title":"Developments in Viral Vector-Based Vaccines.","volume":"2","author":"T Ura","year":"2014","journal-title":"Vaccines (Basel)."},{"key":"ref-21","doi-asserted-by":"publisher","first-page":"576-577","DOI":"10.1038\/d41586-020-01221-y","article-title":"The race for coronavirus vaccines: A graphical guide.","volume":"580","author":"E Callaway","year":"2020","journal-title":"Nature."},{"key":"ref-22","doi-asserted-by":"publisher","first-page":"56-78","DOI":"10.1016\/j.addr.2014.10.002","article-title":"Live attenuated and inactivated viral vaccine formulation and nasal delivery: Potential and challenges.","volume":"93","author":"J Tlaxca","year":"2015","journal-title":"Adv Drug Deliv Rev."},{"key":"ref-23","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.3389\/fimmu.2019.01250","article-title":"Attenuation of Human Respiratory Viruses by Synonymous Genome Recoding.","volume":"10","author":"C Le Nou\u00ebn","year":"2019","journal-title":"Front Immunol."},{"key":"ref-24","doi-asserted-by":"publisher","first-page":"2943-8","DOI":"10.1016\/j.vaccine.2020.02.056","article-title":"A codon-pair deoptimized live-attenuated vaccine against respiratory syncytial virus is immunogenic and efficacious in non-human primates.","volume":"38","author":"S Mueller","year":"2020","journal-title":"Vaccine."},{"key":"ref-25","doi-asserted-by":"publisher","first-page":"10525-40","DOI":"10.1128\/JVI.01565-14","article-title":"Influenza A Virus Attenuation by Codon Deoptimization of the NS Gene for Vaccine Development.","volume":"88","author":"A Nogales","year":"2014","journal-title":"J Virol."},{"key":"ref-26","doi-asserted-by":"publisher","first-page":"35-49","DOI":"10.7774\/cevr.2012.1.1.35","article-title":"Principles underlying rational design of live attenuated influenza vaccines.","volume":"1","author":"Y Jang","year":"2012","journal-title":"Clin Exp Vaccine Res."},{"key":"ref-27","article-title":"Vaccines"},{"key":"ref-28","article-title":"Vaccines and Preventable Diseases","year":"2018"},{"key":"ref-29","doi-asserted-by":"publisher","first-page":"1845-54","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: A dose-escalation, open-label, non-randomised, first-in-human trial.","volume":"395","author":"F Zhu","year":"2020","journal-title":"Lancet."},{"key":"ref-30","article-title":"NIH A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector) (CTII-nCoV)","year":"2020"},{"key":"ref-31","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2608-y","article-title":"ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques.","author":"N van Doremalen","year":"2020","journal-title":"Nature."},{"key":"ref-32","article-title":"Oxford vaccine: trial on pigs \u2018boosts coronavirus immune response\u2019","author":"A McNamara","year":"2020"},{"key":"ref-33","article-title":"Did The Oxford Covid Vaccine Work In Monkeys? Not Really","author":"W Haseltine","year":"2020"},{"key":"ref-34","article-title":"AstraZeneca to supply Europe with up to 400 million doses of Oxford University\u2019s vaccine at no profit","author":"A Kemp","year":"2020"},{"key":"ref-35","article-title":"Oxford COVID-19 vaccine trials move to stage 3 human trials","author":"A Laguipo","year":"2020"},{"key":"ref-36","doi-asserted-by":"publisher","first-page":"373-417","DOI":"10.1016\/B0-08-045044-X\/00214-5","article-title":"7.13 - Ribonucleic Acid Viruses: Antivirals for Influenza A and B, Hepatitis C Virus, and Respiratory Syncytial Virus","author":"U Schmitz","year":"2017"},{"key":"ref-37","doi-asserted-by":"publisher","first-page":"695-719","DOI":"10.1586\/erv.12.38","article-title":"Inactivated virus vaccines from chemistry to prophylaxis: Merits, risks and challenges.","volume":"11","author":"I Delrue","year":"2012","journal-title":"Expert Rev Vaccines."},{"key":"ref-38","doi-asserted-by":"publisher","first-page":"934-8","DOI":"10.15585\/mmwr.mm6535a3","article-title":"Cessation of Trivalent Oral Poliovirus Vaccine and Introduction of Inactivated Poliovirus Vaccine - Worldwide, 2016.","volume":"65","author":"L Hampton","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"ref-39","doi-asserted-by":"publisher","first-page":"2020.04.17.046375","DOI":"10.1101\/2020.04.17.046375","article-title":"Rapid development of an inactivated vaccine for SARS-CoV-2.","author":"Q Gao","year":"2020","journal-title":"bioRxiv."},{"key":"ref-40","doi-asserted-by":"publisher","first-page":"607-18","DOI":"10.1586\/erv.09.19","article-title":"Vero cell platform in vaccine production: Moving towards cell culture-based viral vaccines.","volume":"8","author":"P Barrett","year":"2009","journal-title":"Expert Rev Vaccines."},{"key":"ref-41","doi-asserted-by":"publisher","first-page":"1443-60","DOI":"10.1002\/bit.24493","article-title":"Vaccine process technology.","volume":"109","author":"J Josefsberg","year":"2012","journal-title":"Biotechnol Bioeng."},{"key":"ref-42","doi-asserted-by":"publisher","first-page":"e04531","DOI":"10.7554\/eLife.04531","article-title":"RNA virus attenuation by codon pair deoptimisation is an artefact of increases in CpG\/UpA dinucleotide frequencies.","volume":"3","author":"F Tulloch","year":"2014","journal-title":"Elife."},{"key":"ref-43","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41587-019-0385-7","article-title":"First Ebola vaccine approved.","volume":"38","year":"2020","journal-title":"Nat Biotechnol."},{"key":"ref-44","article-title":"Griffith University researchers on the road to COVID-19 vaccine","author":"D Marshall","year":"2020"},{"key":"ref-45","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/vaccines4020012","article-title":"Recent Advances in Subunit Vaccine Carriers.","volume":"4","author":"A Vartak","year":"2016","journal-title":"Vaccines (Basel)."},{"key":"ref-46","article-title":"MODULE 2: Types of Vaccine and Adverse Reactions","year":"2020"},{"key":"ref-47","doi-asserted-by":"publisher","first-page":"e02187-18","DOI":"10.1128\/JVI.02187-18","article-title":"Rational Design of Zika Virus Subunit Vaccine with Enhanced Efficacy.","volume":"93","author":"W Tai","year":"2019","journal-title":"J Virol."},{"key":"ref-48","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1038\/s41598-018-19456-1","article-title":"Novel Immunoinformatics Approaches to Design Multi-epitope Subunit Vaccine for Malaria by Investigating Anopheles Salivary Protein.","volume":"8","author":"R Pandey","year":"2018","journal-title":"Sci Rep."},{"key":"ref-49","doi-asserted-by":"publisher","first-page":"163-74","DOI":"10.1111\/j.1365-2567.2004.01971.x","article-title":"Haemophilus influenzae type b conjugate vaccines.","volume":"113","author":"D Kelly","year":"2004","journal-title":"Immunology."},{"key":"ref-50","first-page":"1488-91","article-title":"[Protein subunit vaccines: example of vaccination against hepatitis B virus].","volume":"45","author":"F Degos","year":"1995","journal-title":"Rev Prat."},{"key":"ref-51","article-title":"ExpreS2ion announces EU grant award for the COVID-19 vaccine development programme","year":"2020"},{"key":"ref-52","doi-asserted-by":"publisher","first-page":"597","DOI":"10.3389\/fimmu.2018.00597","article-title":"Modulation of Dengue\/Zika Virus Pathogenicity by Antibody-Dependent Enhancement and Strategies to Protect Against Enhancement in Zika Virus Infection.","volume":"9","author":"R Khandia","year":"2018","journal-title":"Front Immunol."},{"key":"ref-53","doi-asserted-by":"publisher","first-page":"e02015-19","DOI":"10.1128\/JVI.02015-19","article-title":"Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry.","volume":"94","author":"Y Wan","year":"2020","journal-title":"J Virol."},{"key":"ref-54","doi-asserted-by":"publisher","first-page":"339-41","DOI":"10.1038\/s41577-020-0321-6","article-title":"The potential danger of suboptimal antibody responses in COVID-19.","volume":"20","author":"A Iwasaki","year":"2020","journal-title":"Nat Rev Immunol."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/9-991\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/9-991\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/9-991\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T12:45:13Z","timestamp":1597668313000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/9-991\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,17]]},"references-count":54,"URL":"https:\/\/doi.org\/10.12688\/f1000research.25998.1","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.28692.r69046","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.28692.r69047","asserted-by":"subject"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,17]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/9-991\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.28692.r69046, Shinji Makino, Department of Microbiology and Immunology, Institute for Human Infection and Immunity, University of Texas Medical Branch, Galveston, TX, USA, 17 Aug 2020, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/9-991\/v1#referee-response-69046","order":0,"name":"referee-response-69046","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.28692.r69047, Gavin Koh, Diseases of the Developing World, GlaxoSmithKline, Uxbridge, UB11 1BT, UK, 17 Aug 2020, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/9-991\/v1#referee-response-69047","order":1,"name":"referee-response-69047","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"SM is the recipient of a National Health and Medical Research Council (NHMRC) Senior Research Fellowship (APP11544347). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.","order":2,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}